42 related articles for article (PubMed ID: 10376769)
1. The geometry of phenotypic evolution in developmental hyperspace.
Wolf JB
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15849-51. PubMed ID: 12461185
[No Abstract] [Full Text] [Related]
2. Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans.
Céspedes-Garro C; Jiménez-Arce G; Naranjo ME; Barrantes R; Llerena A;
Rev Biol Trop; 2014 Dec; 62(4):1659-71. PubMed ID: 25720195
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.
Zhou Y; Lauschke VM
Hum Genet; 2022 Jun; 141(6):1113-1136. PubMed ID: 34652573
[TBL] [Abstract][Full Text] [Related]
4. Genomewide Association Studies in Pharmacogenomics.
McInnes G; Yee SW; Pershad Y; Altman RB
Clin Pharmacol Ther; 2021 Sep; 110(3):637-648. PubMed ID: 34185318
[TBL] [Abstract][Full Text] [Related]
5. Opportunities and challenges for the computational interpretation of rare variation in clinically important genes.
McInnes G; Sharo AG; Koleske ML; Brown JEH; Norstad M; Adhikari AN; Wang S; Brenner SE; Halpern J; Koenig BA; Magnus DC; Gallagher RC; Giacomini KM; Altman RB
Am J Hum Genet; 2021 Apr; 108(4):535-548. PubMed ID: 33798442
[TBL] [Abstract][Full Text] [Related]
6. Massively parallel variant characterization identifies
Suiter CC; Moriyama T; Matreyek KA; Yang W; Scaletti ER; Nishii R; Yang W; Hoshitsuki K; Singh M; Trehan A; Parish C; Smith C; Li L; Bhojwani D; Yuen LYP; Li CK; Li CH; Yang YL; Walker GJ; Goodhand JR; Kennedy NA; Klussmann FA; Bhatia S; Relling MV; Kato M; Hori H; Bhatia P; Ahmad T; Yeoh AEJ; Stenmark P; Fowler DM; Yang JJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5394-5401. PubMed ID: 32094176
[TBL] [Abstract][Full Text] [Related]
7. Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen.
Ariza Márquez YV; Briceño I; Aristizábal F; Niño LF; Yosa Reyes J
Sci Rep; 2019 Feb; 9(1):2521. PubMed ID: 30792473
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.
Céspedes-Garro C; Naranjo MG; Rodrigues-Soares F; LLerena A; Duconge J; Montané-Jaime LK; Roblejo H; Fariñas H; Campos ML; Ramírez R; Serrano V; Villagrán CI; Peñas-LLedó EM
Pharmacogenomics; 2016 Oct; 17(15):1707-1724. PubMed ID: 27633613
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients.
Parker K; Aasebø W; Haslemo T; Stavem K
Springerplus; 2016; 5():350. PubMed ID: 27066364
[TBL] [Abstract][Full Text] [Related]
10. Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival.
Martins DM; Vidal FC; Souza RD; Brusaca SA; Brito LM
Braz J Med Biol Res; 2014 Nov; 47(11):1008-15. PubMed ID: 25296365
[TBL] [Abstract][Full Text] [Related]
11. African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.
Bains RK
Evol Med Public Health; 2013 Jan; 2013(1):118-34. PubMed ID: 24481193
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.
Dorado P; Heras N; Machín E; Hernández F; Teran E; Llerena A
Eur J Clin Pharmacol; 2012 May; 68(5):637-44. PubMed ID: 22083166
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
López M; Guerrero J; Jung-Cook H; Alonso ME
Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
[TBL] [Abstract][Full Text] [Related]
16. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations.
Jorge LF; Eichelbaum M; Griese EU; Inaba T; Arias TD
Pharmacogenetics; 1999 Apr; 9(2):217-28. PubMed ID: 10376769
[TBL] [Abstract][Full Text] [Related]
17. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica].
Jorge LF; Arias TD
Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827
[TBL] [Abstract][Full Text] [Related]
18. Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine.
Jorge-Nebert LF; Eichelbaum M; Griese EU; Inaba T; Arias TD
Pharmacogenetics; 2002 Jan; 12(1):39-48. PubMed ID: 11773863
[TBL] [Abstract][Full Text] [Related]
19. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
